抑制BRD9克服了在质母细胞瘤中抗瘤病毒治疗的耐药性
Chen Guo1, Zhilin Long2, Peng Lin3
1College of Life Sciences, Zhejiang University, Hangzhou 310058, China; Key Laboratory of Growth Regulation and Transformation Research of Zhejiang Province, School of Life Sciences, Westlake University, Hangzhou 310030, China; Westlake Disease Modeling Laboratory, Westlake Laboratory of Life Sciences and Biomedicine, Hangzhou 310030, China; School of Life Sciences, Westlake University, Hangzhou 310030, China.
Cell reports. Medicine
|July 31, 2025
概括
研究人员确定了含多马因的蛋白9 (BRD9) 作为质母细胞瘤对型病毒治疗的抗性的一个关键因素. 抑制BRD9可以提高治疗效率和抗瘤免疫力,提供新的治疗点.
科学领域:
- 在瘤学瘤学.
- 病毒学 病毒学
- 遗传学 遗传学 是一个
背景情况:
- 多形质母细胞瘤 (GBM) 对患者的长期存活构成重大挑战.
- 瘤溶解性病毒疗法显示出有希望的结果,但在许多患者中面临阻力.
- 识别瘤内在耐药性因素对于改善治疗结果至关重要.
研究的目的:
- 鉴定导致质母细胞瘤对性病毒疗法耐药性的遗传因素.
- 研究非正规BRG1/BRM关联因子 (ncBAF) 综合体在治疗耐药性的作用.
- 为了评估含有odomain的蛋白9 (BRD9) 作为潜在的治疗点.
主要方法:
- 进行了CRISPR查,以确定涉及型病毒疗法耐药性的基因.
- 在质母细胞瘤模型中使用型简单疹病毒1型 (oHSV1).
- 评估了BRD9淘汰和抑制对oHSV1疗效和抗瘤免疫力的影响.
- 分析了BRD9在抗病毒基因表达中的作用的分子机制.
主要成果:
- 鉴定了ncBAF复合体,特别是BRD9,作为抗性病毒治疗耐药性的关键因素.
- 淘汰BRD9显著提高了oHSV1的疗效,并提高了抗瘤免疫力.
- 在各种GBM模型中,BRD9与IBRD9的抑制改善了oHSV1活性.
- 发现BRD9结合RELA,增强抗病毒基因的表达.
结论:
- BRD9 是一个关键的瘤内在因素,在质母细胞瘤中驱动对oHSV1的抗性.
- 向BRD9是一个有前途的策略,以克服抗菌性病毒疗法耐药性.
- 降低BRD9水平与临床试验中更好的结果相关,支持其作为治疗点的作用.
相关概念视频
02:56Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
02:49Cancer Therapies
8.0K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
8.0K